Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer
NCT ID: NCT05529615
Last Updated: 2022-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
2684 participants
INTERVENTIONAL
2022-11-01
2029-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In recent years, circulating tumor DNA had achieved encouraging results in monitoring recurrence and metastasis after surgery, and has potential clinical application value. Postoperative ctDNA is also considered as a marker of increased risk of recurrence for stage I-III colon cancer and can provide predictive information for decision making on adjuvant treatment.
The results of GERCOR-PRODIGE, concomitant study of IDEA-FRANCE, showed that in the high-risk group, the patients with ctDNA positive and receiving adjuvant chemotherapy for 6 months had similar prognosis as the patients with ctDNA negative and receiving chemotherapy for 3 months; in the low-risk group, the patients with ctDNA positive but receiving chemotherapy for 3 months had worst prognosis, and the prognosis of patients with ctDNA negative chemotherapy for 3 months and 6 months and ctDNA positive chemotherapy for 6 months were similar. This indicates that risk stratification can be further performed according to the results of ctDNA after clinical pathological staging. Pathological staging is still an important decision-making factor for chemotherapy. It is not reliable to the chemotherapy decision making just based on ctDNA and abandoning clinical staging.
Therefore, a prospective, multicenter, open-label, randomized controlled clinical trial was designed aimed to investigate circulating tumor DNA guided adjuvant chemotherapy for colon cancer. In this study, all the patients are divided into high-risk group and low-risk group according to the postoperative pathology. Patients in each group were randomized to different treatment schedule according to the results of ctDNA.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer
NCT05131243
Colon Cancer Treatment Decisions and Recurrence Predicting
NCT02997241
Use of ctDNA for Monitoring of Stage III Colorectal Cancer
NCT02842203
Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III
NCT02556281
ctDNA as a Prognostic Marker for Postoperative Relapse in Early and Intermediate Stage Colorectal Cancer
NCT03312374
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
stage II with high risk and stage III with low risk（T1-3N1）
ctDNA will be detected at 7 days after surgical treatment. If，ctDNA(-)-\> observation； ctDNA(+)-\> 1:1 randomized as Capeox chemotherapy 3 months and observation. CtDNA will be detected at 4 months after surgical treatment.
detection of ctDNA
the ctDNA will be detected during the treatment and served as the andomization basis
stage III with high risk（T4 or N2 or both）
ctDNA will be detected at 7 days after surgical treatment. All the stage III with high risk will receive Capeox chemotherapy 3 months. ctDNA will be detected after the completion of Capeox chemotherapy 3 months. If，ctDNA(-) -\> observation； ctDNA(+) -\> 1:2 randomized as Capeox chemotherapy 3 monthsand second line treatment（decided by physician）.
CtDNA will be detected at 7 months after surgical treatment.
detection of ctDNA
the ctDNA will be detected during the treatment and served as the andomization basis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
detection of ctDNA
the ctDNA will be detected during the treatment and served as the andomization basis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Colon adenocarcinoma confirmed by pathology (including high and high differentiated tubular adenocarcinoma, papillary adenocarcinoma, low differentiated adenocarcinoma, mucinous adenocarcinoma and signet ring cell carcinoma)
3. Postoperative pathology is stage II with high-risk factors or stage III;
High risk stage II refers to stage II colon cancer with at least one of the following:
a) T4 stage; b) The number of lymph nodes detected was less than 12; c) Poor differentiation (except MSI-H); d) Complicated with LVI or PNI；e) Complicated with obstruction or perforation.
4. No distant metastasis was found in preoperative imaging examination and operation;
5. ECOG score: 0-2 points;
6. MSS/pMMR and BRAF wild type
7. Start time of chemotherapy is less than 2 months from the operation
8. Have sufficient organ functions;
9. The baseline blood routine and biochemical indexes of the subject meet the following standards:
* hemoglobin ≥ 9.0 g / dl;
* absolute neutrophil count (ANC) ≥ 1500 / mm3;
* platelet count ≥ 100000 / mm3;
* total bilirubin ≤ 1.5 times the upper limit of normal value (ULN);
* glutamic pyruvic transaminase and glutamic oxalic transaminase ≤ 2.5 times ULN;
* creatinine ≤ 1.5 times ULN;
10. Patients or family members who can understand the study protocol and are willing to participate in the study shall provide written informed consent.
Exclusion Criteria
2. History of malignant tumor in the past 5 years (except fully cured cervical carcinoma in situ or basal cell carcinoma or squamous epithelial cell skin cancer)
3. Pregnant women
4. Serious mental illness
5. Those with poor physical condition and difficult to complete chemotherapy
6. Patients or family members cannot understand the conditions and objectives of this study
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Cancer Hospital & Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aiwen Wu
Director of GI cancer III
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aiwen Wu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Peking University Cancer Hospital & Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking university cancer hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PKUCH-C03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.